Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Short Communication Volume 7 Issue 6

Advances in Glioma Treatment with Utilization of Enzyme - Stimulated Chemodynamic Therapy - Through a Peptides - H2S Donor Conjugate Complexed with Fe2+ -- A Short Communication

Kulvinder Kochar Kaur1*, Gautam Allahbadia2 and Mandeep Singh3

1Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
2Scientific Director, Rotunda-A Centre for Human Reproduction, Mumbai, India
3Consultant Neurologist, Swami Satyan and Hospital, Jalandhar, Punjab, India

*Corresponding Author: Kulvinder Kochar Kaur, Scientific Director, Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India.

Received: July 14, 2023; Published: July 25, 2023


It has been reasoned out that induction of greater quantities of Reactive oxygen (ROS) with in the tumor cells is a cancer treatment strategy known as Chemodynamic therapy (CDT). Depending on the administration of Fenton reaction facilitators like Fe2+, CDT benefits from the fact that over generated ROS amongst the tumor microenvironment. Production of a peptides- H2S donor conjugate (PHDC) which was complexed with Fe2+ known as AAN-PTC- Fe2+ was achieved by Zhu., et al. This AAN-tripeptide was particularly cleaved by legumain, an enzyme which was over expressed in glioma cells for liberation of carbonyl Sulfide (COS). Whereas COS hydrolysis by enzyme carbonic anhydrase (CA) which generated H2S, a hampering agent of catalase (CAT), an enzyme which leads to detoxification of H2O2. Fe2+ in combination with H2S escalated intracellular ROS quantities as well as diminished viability in C6 glioma cells in contrast to controls having absence of either Fe2+, AAN sequence or capacity of production of H2S. AAN-PTC- Fe2+ worked better compared to temozolomide whereas demonstrating no cytotoxicity against cardiomyocytes. Hence this study illustrated an H2S-augmented, enzyme responding manifesto regarding synergistic cancer treatment.

 Keywords: H2S donor; Reactive Oxygen;


  1. Zeng L., et al. “Selenium -platinum coordination compounds as novel anti cancer drugs: selectively killing cancer cells via a Reactive oxygen (ROS)mediated route”. Chemistry: An Asian Journal8 (2014): 2295-2302.
  2. Zhang C., et al. Angewandte Chemie International Edition 55 (2016): 2101-2106.
  3. Li X., et al. “Protein- delivering nanocomplexes with Fenton reaction-triggered cargo release to boost Cancer Immunotherapies”. ACS Nano 16 (2022): 14982-14999.
  4. Kulvinder Kochar Kaur., et al. “An update on the Screening, diagnosis &Management of Breast Cancer –A Review with considerations for future fertility”. International Journal of Medical and all body Health Research 2 (2021): 40-53.
  5. Wang RH., et al. “The Hidden Role of Hydrogen Sulfide Metabolism in Cancer”. International Journal of Molecular Sciences 22 (2021): 6562.
  6. Lia H., et al. “Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer”. Redox Biology 34 (2020): 101564.
  7. Benetti LR., et al. “Hydrogen Sulfide inhibits Oxidative stress in lungs from Allergic mice”. European Journal of Pharmacology 698 (2013): 463-469.
  8. Kashfi K. “Nitric oxide in cancer and beyond”. Biochemistry and Pharmacology 149 (2018): 205-223.
  9. Bao S., et al. “Stem cells like glioma cells promote tumor angiogenesis vascular endothelial growth factors”. Cancer Research16 (2006): 7843-7848.
  10. Miller KD., et al. “Brain and other central nervous system tumor statistics”. CA: A Cancer Journal for Clinicians 71 (2021): 381-406.
  11. Saleh M., et al. “Inhibition of growth of C6 glioma cells in vivo, by expression of antisense vascular endothelial growth factor sequence”. Cancer Research 56 (1996): 393-401.
  12. Ferreira AGK., et al. “Effect of proline on cell death, cell cycle and Oxidative stress in C6 glioma cells line”. Neurotox Research 39 (2021): 327-334.
  13. Goel BV., et al. “In vitro activity of compounds from Glycyrrhiza glabra C6 glioma Cancer cells: identification of natural lead for further evaluation”. Natural Product Research 35 (2021): 5489-5492.
  14. Zhen Y., et al. “Clinicopathologic significance of legumain over expression in Cancer: a systematic review and meta-analysis”. Scientific Report 5 (2015): 16599.
  15. Zhu Y., et al. “Enzyme triggered chemodynamictherapy via a peptides- H2S donor conjugate complexed with Fe2+”. Angewandte Chemie International Edition22 (2023): e202302303.


Citation: Kulvinder Kochar Kaur., et al. “Advances in Glioma Treatment with Utilization of Enzyme - Stimulated Chemodynamic Therapy - Through a Peptides - H2S Donor Conjugate Complexed with Fe2+ -- A Short Communication" Acta Scientific Cancer Biology 7.6 (2023): 22-25.


Copyright: © 2023 Kulvinder Kochar Kaur., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 20, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US